Evidence map›Paper›PMID 39996757›Full record

ArticleCells2025

Youth Who Control HIV on Antiretroviral Therapy Display Unique Plasma Biomarkers and Cellular Transcriptome Profiles Including DNA Repair and RNA Processing.

Samiksha A Borkar, Li Yin, Guglielmo M Venturi, Jerry Shen, Kai-Fen Chang, Bernard M Fischer, Upasana Nepal, Isaac D Raplee, John W Sleasman, Maureen M Goodenow

Abstract read
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Samiksha A BorkarMolecular HIV and Host Interactions Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Bethesda, MD 20894, USA.
Li YinMolecular HIV and Host Interactions Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Bethesda, MD 20894, USA.
Guglielmo M VenturiDivision of Allergy and Immunology, Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA.
Jerry ShenMolecular HIV and Host Interactions Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Bethesda, MD 20894, USA.
Kai-Fen ChangMolecular HIV and Host Interactions Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Bethesda, MD 20894, USA.ORCID 0000-0003-3893-7176
Bernard M FischerDivision of Allergy and Immunology, Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0001-8066-0516
Upasana NepalMolecular HIV and Host Interactions Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Bethesda, MD 20894, USA.
Isaac D RapleeMolecular HIV and Host Interactions Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Bethesda, MD 20894, USA.
John W SleasmanDivision of Allergy and Immunology, Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA.
Maureen M GoodenowMolecular HIV and Host Interactions Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Bethesda, MD 20894, USA.

Funding

Adol. Medicine Trials Network for HIV/AIDS InterventionsU01HD040474 · NICHD · WESTAT, INC. · PI HARRIS, DONALD ROBERT · 2001 to 2016
$114.4M
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupU01AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI JACKSON, J BROOKS · 2006 to 2010
$109.7M
LEADERSHIP GROUP FOR ADOLESCENT MEDICINE TRIALS NETWORKU01HD040533 · NICHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WILSON, CRAIG M · 2001 to 2016
$76.4M
INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025780 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$61.3M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
UVDM01RR010284 · NCRR · HOWARD UNIVERSITY · PI TAYLOR, WILLIAM ROBERT · 1996 to 2010
$17.4M
ZAP-70 EXPRESSION, CD38 EXPRESSION AND PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIAM01RR020359 · NCRR · CHILDREN'S RESEARCH INSTITUTE · PI BATSHAW, MARK L. · 2005 to 2010
$13.8M
Substance Use and Immunity in HIV+ Adolescents by Systems BiologyR01DA031017 · NIDA · UNIVERSITY OF FLORIDA · PI YIN, LI · 2010 to 2014
$4.4M
Consequences of marijuana use on inflammatory pathways in HIV-infected youthU01DA044571 · NIDA · DUKE UNIVERSITY · PI SLEASMAN, JOHN W. · 2017 to 2021
$2.9M
Duke University Center for AIDS Research 5P30-AI064518NCRR NIH HHS M01 RR010284NCRR NIH HHS M01 RR020359NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1 RR025780NIAID NIH HHS P30 AI064518NIAID NIH HHS U01 AI068632NICHD NIH HHS U01 HD040474NICHD NIH HHS U01 HD040533NIDA NIH HHS R01 DA031017NIDA NIH HHS U01 DA044571NIH HHS R01-DA031017NIH HHS U01-DA044571NIH HHS U01-HD040474NIH HHS U01-HD040533NIH Intramural Research Program NIAID
6 · The paper itself

Abstract

Combination antiretroviral therapy (ART) suppresses detectible HIV-1 replication, but latent reservoirs and persistent immune activation contribute to residual viral-associated morbidities and potential viral reactivation. youth with HIV (YWH) virally suppressed on ART early in infection before CD4 T cell decline with fewer comorbidities compared to adults represent a critical population for identifying markers associated with viral control and predictors of viral breakthrough. This study employed a multi-omics approach to evaluate plasma biomarkers and cellular gene expression profiles in 52 participants, including 27 YWH on ART for 144 weeks and 25 youth with no infection (NI) (ages 18-24). Among the 27 YWH, 19 were virally suppressed (VS; <50 RNA copies/mL), while eight were non-suppressed (VNS; >50 RNA copies/mL). VS YWH displayed unique bioprofiles distinct from either VNS or NI. Early viral suppression mitigates inflammatory pathways and normalizes key biomarkers associated with HIV-related comorbidities. Genes upregulated in pathways linked to cellular homeostasis such as DNA repair, RNA processing, and transcription regulation may diminish viral breakthrough and maintain sustained HIV control on ART. Candidate markers and putative molecular mechanisms were identified, offering potential therapeutic targets to limit viral persistence, enhance HIV treatment strategies, and pave the way for improved clinical outcomes.

Indexed as

BiomarkersDNA RepairHIV InfectionsRNA Processing, Post-TranscriptionalTranscriptomeAdolescentFemaleHIV-1HumansMaleViral LoadYoung AdultBiomarkersbiomarkersbioprofilescellular homeostasiscomorbiditiesDNA repairinflammationtranscriptomeviral suppressionyouth with HIV

Identifiers

PMID39996757
PMCPMC11853983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.